35.53
전일 마감가:
$33.73
열려 있는:
$33.89
하루 거래량:
21.01M
Relative Volume:
1.95
시가총액:
$13.67B
수익:
$5.06B
순이익/손실:
$-2.22B
주가수익비율:
-6.1048
EPS:
-5.82
순현금흐름:
$-3.96B
1주 성능:
+7.70%
1개월 성능:
-1.00%
6개월 성능:
-59.00%
1년 성능:
-59.44%
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
MRNA
Moderna Inc
|
35.53 | 13.67B | 5.06B | -2.22B | -3.96B | -5.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
모더나 Stock (MRNA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
2024-12-10 | 재개 | BofA Securities | Underperform |
2024-11-19 | 개시 | Berenberg | Hold |
2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
2024-11-15 | 개시 | Wolfe Research | Underperform |
2024-10-17 | 개시 | Bernstein | Mkt Perform |
2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
2023-11-29 | 개시 | Canaccord Genuity | Hold |
2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2023-07-24 | 개시 | William Blair | Mkt Perform |
2023-07-14 | 개시 | HSBC Securities | Reduce |
2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
2023-04-26 | 개시 | Guggenheim | Neutral |
2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
2022-01-21 | 개시 | UBS | Neutral |
2021-12-07 | 개시 | Cowen | Market Perform |
2021-11-09 | 개시 | Wolfe Research | Outperform |
2021-10-22 | 개시 | Deutsche Bank | Sell |
2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2021-07-15 | 재확인 | Jefferies | Hold |
2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
2020-11-23 | 개시 | Wells Fargo | Equal Weight |
2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-07-13 | 개시 | Jefferies | Buy |
2020-06-30 | 개시 | Argus | Buy |
2020-06-08 | 개시 | Barclays | Overweight |
2020-04-30 | 개시 | BMO Capital Markets | Outperform |
2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2019-12-03 | 재개 | BofA/Merrill | Buy |
2019-10-25 | 개시 | ROTH Capital | Buy |
2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
CIBC Asset Management Inc Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock: The Future Unveiled! Innovative Tech to Drive Explosive Growth! - Reporteros del Sur -
Market plunges after new Coronavirus reported in Wuhan but Pfizer and Moderna stock soars - Daily Mail
Why Moderna Inc. (MRNA) Surged On Friday? - Insider Monkey
Moderna (NASDAQ:MRNA) Trading 8.8% HigherWhat's Next? - MarketBeat
Moderna and Other Vaccine Stocks Climb After Coronavirus News From China - MSN
Chinese researchers find bat virus enters human cells via same pathway as COVID -February 21, 2025 at 05:56 pm EST - Marketscreener.com
Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China - Yahoo Finance
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Trading Up 8.8%Time to Buy? - MarketBeat
Moderna (NASDAQ:MRNA) Trading Down 7.9% Following Analyst Downgrade - MarketBeat
Moderna, Novavax rise as new bat coronavirus identified in China - MSN
Moderna stock rises amid new virus concerns By Investing.com - Investing.com Australia
Analyst calls of the week: Rivian, Block, Moderna, Bumble... - Proactive Investors USA
Moderna, Inc. SEC 10-K Report - TradingView
Rx Rundown: Moderna, Sanofi, GSK and more - MM+M Online
Meitav Investment House Ltd. Sells 184,043 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release? - MSN
Moderna, Inc. to Host Earnings Call - ACCESS Newswire
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Baillie Gifford & Co. Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNA - ACCESS Newswire
Moderna (NASDAQ:MRNA) Price Target Lowered to $78.00 at UBS Group - MarketBeat
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion - MSN
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - Nasdaq
Moderna (MRNA) Expected to Announce Earnings on Thursday - MarketBeat
Intrinsic Value Partners LLC Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna's (MRNA) "Sector Perform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Wall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now? - MSN
EMA Urged Pfizer And Moderna To Boost Production Volume Of COVID Vax - BW Healthcare World
UBS Adjusts Moderna Price Target to $78 From $96, Maintains Buy Rating -February 19, 2025 at 10:21 am EST - Marketscreener.com
Why Moderna (MRNA) Went Up on Tuesday? - Yahoo Finance
Moderna: A Generational Opportunity for Investors in 2025 - MarketBeat
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health - Quantisnow
Moderna (NASDAQ:MRNA) Stock Rating Lowered by Barclays - MarketBeat
Moderna price target lowered to $78 from $96 at UBS - TipRanks
Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom - BioSpace
Barclays Downgrades Moderna (WBAG:MRNA) - Nasdaq
Rep. Julie Johnson Sells Moderna, Inc. (NASDAQ:MRNA) Shares - MarketBeat
Louisiana State Employees Retirement System Sells 30,100 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Q4 2024 Earnings Call Transcript - MSN
Barclays Downgrades Moderna (MRNA) - MSN
Barclays Downgrades Moderna (BIT:1MRNA) - Nasdaq
Moderna Downgraded by Barclays as Policy Risks and Weak Revenue Weigh on Outlook - GuruFocus.com
Why Moderna (MRNA) Stock Is Up Today By Stock Story - Investing.com Canada
Moderna's Stock Increases by 11.8% Despite Market ChallengesNews and Statistics - IndexBox, Inc.
MRNA: Moderna Stock Rises on Financial Results Despite Downgrade - GuruFocus.com
Moderna rises 8% even as Barclays downgrades - Seeking Alpha
Moderna shares move higher as investors look beyond Q4 losses - Proactive Investors UK
Why Moderna (MRNA) Stock Is Up Today - Financial Content
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges - Benzinga
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):